Abstract
Overview
Introduction
Influenza is a highly infectious disease which globally infects 10-20% of the
population every year causing up to 500,000 deaths. Although all persons are
at risk, the elderly and the young are the most vulnerable. For decades,
trivalent prophylactic vaccines produced in chicken eggs have been used to
reduce the burden of influenza with approximately 300 million doses produced
globally.
Scope
- Evaluation of total 2004 global vaccine market value, historical growth
since 1999 and major company market share
- Overview of major influenza vaccine products, producers and new product
development
- Expert led discussion of drivers and resistors to cell culture flu systems
in seasonal/pandemic scenarios
- Forecast value and demand (doses) for influenza vaccines in 2010 with
launch predictions
Report Highlights
Despite the Chiron debacle, collective sales of influenza vaccines from
Western producers surpassed the $1 billion level in 2004 with 10% growth over
the previous year. Expanding recommendations for vaccination continue to fuel
global demand.
Datamonitor forecasts that in the seven major markets demand for influenza
vaccines will expand to 370 million doses and a market value of $3.7 billion
by 2010. Global capacity will expand appropriately to meet this goal but
competition will intensify with 11 predicted new product launches.
Cell culture flu could amount to 15% of US doses supplied in 2010 if the FDA
can overcome safety concerns with the MDCK line. Although heralded as a much
needed solution, cell culture flu still requires substantial capital
investment.
Reasons to Purchase
- Review an up to date expert discussion of major dynamics within the global
vaccine market
- Gain insight into how the market for influenza vaccines is now an
attractive growth option
- Understand commercial drivers and resistors for cell culture flu systems
View Cart
